Expectancy effects and compromised blinding impact psychiatric RCTs. This review offers mitigation strategies. #PsychiatryRsearch PMID:40072447, JAMA Psychiatry 2025, JAMA Psychiatry doi.org/10.1001/jamaps… #AI #Pharma #BioMed #RNA #ASHG #ESHG

⚠️ ⚠️ Very important paper for #evidence #synthesis researchers ⚠️⚠️ Led by the amazing Corentin Gosling from Université Paris Nanterre Out in Research Synthesis Methods cambridge.org/core/journals/…

Our thoughts on missing data, statistics and placebo effects in psychiatric trials. Thanks Samuele Cortese and Marco Solmi! JAMA Psychiatry jamanetwork.com/journals/jamap…

Like alcohol and cannabis… but also no better than placebo? The mixed messaging is staggering. That alone should raise eyebrows- Prof is making it up as she goes along. Hard to take seriously as science. Its messaging for those wanting to just join the ‘antidepressants

Understanding Placebo Mechanisms to Reduce Attrition in Psychiatric Trials jamanetwork.com/journals/jamap… via Nathan Huneke et al

In The Lancet Psychiatry #ADHD Edoardo G. Ostinelli Andrea Cipriani thelancet.com/journals/lanps…

"How are race and ethnicity reported and represented across randomized clinical trials (RCTs) of pharmacotherapies for mental disorders?" Check our paper just published in JAMA Psychiatry! jamanetwork.com/journals/jamap…

In our new study in JAMA Psychiatry led by the amazing Alessio Bellato from University of Southampton, we analysed 1683 randomised controleld trials and found underrepresentation of certain racial and ethnic groups jamanetwork.com/journals/jamap…

Press release from University of Southampton southampton.ac.uk/news/2025/05/r…

This meta-analysis identified gaps in the reporting and representation of race and ethnicity in mental disorder pharmacotherapy trials. ja.ma/42L9tSx

🧵THREAD: Our new study published in #lancetpsych! We found that pramipexole augmentation substantially reduced depressive symptoms in patients with treatment-resistant depression over 48 weeks of treatment. This is an important advance in how we treat depression! 1/6

Trials of drugs for treatment resistant depression are like buses. You wait ages and then two come along at once. First the pramipexole phase 2 in The Lancet and now this.

🧵Not Everything Is Withdrawal 🚨1/9 When ideology overshadows science, patients suffer. A new systematic review in JAMA Psychiatry just released. Let’s talk about what it shows- and why the current withdrawal ONLY narrative risks harming patients. 1/9👇

Is psilocybin as effective for depression as it seems? In a new meta-analysis we look at outcomes after treatment with three types of antidepressants: psilocybin, esketamine and SSRIs. Compared to their own control groups, psilocybin (ES/SMD: 0.70) is clearly more effective ->

Potential clinical academics are being lost to short term funding, lack of protected research time, and rising service demands... We are training some of the world’s brightest doctors, then encouraging them to walk away from the NHS and, in some cases, the UK entirely.

What can *genetic insensitivity to opioids* teach us about endogenous opioid function in humans? Fully funded position in Oslo (PhD student or postdoc) Please RT Interested in pain, mu/kappa opioids, behavioural genetics, RCTs, or related? Apply here: 2411.webcruiter.no/Main2/Recruit/…

📣📣We are hiring! PhD position 👇👇 southampton.ac.uk/study/postgrad…

Great to collaborate on this with Henk van Steenbergen! We found evidence that endogenous opioids mediate attentional broadening after receiving rewards.

It was great to present on placebo and nocebo effects in depressive and anxiety disorders in an educational update session at the ECNP Congress in Amsterdam. Many thanks to the educational committee for inviting me! ECNP

Our new Insights article in European Neuropsychopharmacology! We propose a framework for better design of control conditions for digital therapeutics for mental health conditions. 🔗 authors.elsevier.com/a/1l-8p,L21E2g… ECNP #DigitalTherapeutics #MentalHealth #ClinicalTrials